These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20614555)

  • 1. Learning from failure.
    Nat Rev Drug Discov; 2010 Jul; 9(7):499. PubMed ID: 20614555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.
    Sabbagh MN; Shill HA
    Curr Opin Investig Drugs; 2010 Jan; 11(1):80-91. PubMed ID: 20047162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018.
    Vellas B; Bain LJ; Touchon J; Aisen PS
    J Prev Alzheimers Dis; 2019; 6(3):198-203. PubMed ID: 31062835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's drug update: learn what drugs look promising.
    Lile J
    Nursing; 1997 Feb; 27(2):32lll-32nnn. PubMed ID: 9171601
    [No Abstract]   [Full Text] [Related]  

  • 5. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2018; 107(6):335-336. PubMed ID: 29536808
    [No Abstract]   [Full Text] [Related]  

  • 6. [Advances in Alzheimer's disease treatment].
    Nourhashémi F
    Rev Med Interne; 2006 Aug; 27(8):585-7. PubMed ID: 16782240
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of Alzheimer's disease: rationale and strategies.
    Grundman M; Thal LJ
    Neurol Clin; 2000 Nov; 18(4):807-28. PubMed ID: 11072262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drug treatment for Alzheimer's disease. Doctors want to offer more than sympathy.
    Dening T; Lawton C
    BMJ; 1998 Oct; 317(7163):945. PubMed ID: 9756823
    [No Abstract]   [Full Text] [Related]  

  • 9. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
    Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P;
    Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment for Alzheimer's disease.
    Wilcock GK
    Int J Geriatr Psychiatry; 2000 Jun; 15(6):562-5. PubMed ID: 10861924
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of donepezil in Alzheimer's disease: fact or artifact?
    van Gool WA
    Neurology; 1999 Jan; 52(1):218-9. PubMed ID: 9921890
    [No Abstract]   [Full Text] [Related]  

  • 12. New and different approaches needed for the design and execution of Alzheimer's clinical trials.
    Carrillo MC; Vellas B
    Alzheimers Dement; 2013 Jul; 9(4):436-7. PubMed ID: 23809363
    [No Abstract]   [Full Text] [Related]  

  • 13. Can we do better in developing new drugs for Alzheimer's disease?
    Gauthier S; Scheltens P
    Alzheimers Dement; 2009 Nov; 5(6):489-91. PubMed ID: 19896588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease.
    Farlow MR
    Lancet Neurol; 2009 Jan; 8(1):22-3. PubMed ID: 19042160
    [No Abstract]   [Full Text] [Related]  

  • 15. Merck ends trial of potential Alzheimer's drug verubecestat.
    Hawkes N
    BMJ; 2017 Feb; 356():j845. PubMed ID: 28202490
    [No Abstract]   [Full Text] [Related]  

  • 16. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
    Ehret MJ; Chamberlin KW
    Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing health economic outcome in Alzheimer's disease clinical trials.
    Jonsson L
    J Nutr Health Aging; 2007; 11(4):353-5. PubMed ID: 17653498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's disease clinical trials: where are we now?
    Cummings J
    Can J Neurol Sci; 2006 Feb; 33(1):5. PubMed ID: 16583716
    [No Abstract]   [Full Text] [Related]  

  • 20. New drug treatment for Alzheimer's disease. Treatment with metrifonate warrants multicentre trials.
    Zamar AC; Wise ME; Watson JP
    BMJ; 1998 Oct; 317(7163):946. PubMed ID: 9841012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.